New Study Shows Ozempic and Semaglutide May Lower Risk of Severe Liver Diseases
A nationwide study in Sweden suggests that GLP1 agonists like Ozempic could lower the risk of cirrhosis and liver cancer in individuals with type 2 diabetes and chronic liver disease. This new finding provides a potential life-saving benefit of these medications, offering a new treatment option for preventing severe liver diseases.
Semaglutide: A Revolutionary GLP-1 Receptor Agonist
Semaglutide, an agonist of the glucagon-like peptide-1 (GLP-1) receptor, has been making waves in the field of experimental studies, with researchers touting it as a revolutionary compound. The modest 30 amino acid incretin hormone, GLP-1, has shown significant activity, particularly…
Diabetes Drug Shows Promise in Protecting Against Colorectal Cancer
A recent analysis by researchers in the US suggests that a drug commonly used to treat type 2 diabetes could also be effective in protecting against colorectal cancer (CRC). The drug, known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs), has…